Second-line therapy in colorectal cancer

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 11, 2000, Pages 21-26

  Berlin, Jordan ^a,b  

^a Department of Medicine ^*  (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLFOX PROTOCOL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

CANCER STAGING; COLORECTAL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PHASE 2 CLINICAL TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034569243     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
2. 1a. Saltz LB, Douillard J, Pirotta N, et al: Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (abstract 938). Proc Am Soc Clin Oncol 19:242a, 2000.
3. Saltz LB, Locker PK, Pirotta N, et al: Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients with previously untreated metastatic colorectal cancer (abstract 898). Proc Am Soc Clin Oncol 18:233a, 1999.
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000.
5. Rothenberg ML, Blanke CD: Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 26:632-639, 1999.
6. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998.
7. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996.
8. De Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997.
9. Andre T, Louvet C, Raymond E, et al: Bimonthly high-dose leucovorin, 5-fluorouracil infusion, and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9:1251-1253, 1998.
10. Andre T, Bensmaine MA, Louvet C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999.
11. Maindrault-Goebel F, Louvet C,Andre T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338-1342, 1999.
12. Maindrault-Goebel F, de Gramont A, Louvet C, et al: High-dose oxaliplatin with the simplified 48h bimonthly leucovorin (LV) and 5-fluorouracil (5-FU) regimen in pretreated metastatic colorectal cancer (FOLFOX) (abstract 1017). Proc Am Soc Clin Oncol 18:265a, 1999.